Juno Therapeutics

Biopharma Celgene Corporation (NASDAQ: CELG) reported first-quarter earnings, lowered its 2018 full-year EPS guidance and raised its sales guidance for the year before the open Friday.  What Happened Total net product sales of $3.53 billion in Q1 were 20 percent higher from the same...

Juno Therapeutics Inc (NASDAQ: JUNO) opened sharply higher after reporting third-quarter earnings after the close Wednesday. The report highlighted ASH abstracts on JCAR017, a non-Hodgkin lymphoma drug, showing promising efficacy and solid safety in r/r DLBCL, Barclays analyst Gena Wang said...

Benzinga has featured a look at many investor favorite stocks over the past week. Bearish calls included an iconic industrial and a popular consumer products maker. Bullish calls featured a media giant and the leading EV producer. From the holiday last week to the hurricanes, forest fires and...

Short interest in a number of biotech stocks dwindled in the most recent settlement period. However, two stocks bucked that trend in the first two weeks of July. During the period, the share price of one grew and of the other dropped sharply. Biotechnology is one of those segments that...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by nearly 25 percent to $34.50 ahead of Wednesday's market open. The biopharma company focused on the treatment of cancer announced after Tuesday's market close that the U.S. Food and Drug Administration removed a clinical hold...

Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have gained more nearly 30 percent over the past three months, but are lower by more than 10 percent over the past five days. Despite recent weakness in Juno's stock, the Vetr crowd upgraded the issue to four stars out of a possible five...

While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the April 15 and April 30 settlement dates, three stocks bucked that trend. Biogen Inc (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN) and Juno Therapeutics Inc (NASDAQ: JUNO) saw the number of their...

While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April 15 settlement dates, three stocks bucked that trend. Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) saw the number of their shares...

Mark Cuban thinks that the current (speculated) tech bubble is worse than the one that destroyed dot-com startups more than a decade ago. Not everyone agrees with this assessment, but that doesn't mean there aren't other bubbles investors should avoid. Jason Whitmire, a partner at...

By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals...